<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>30704</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">30704</infon><infon key="article-id_pmid">11305955</infon><infon key="article-id_publisher-id">BCR-3-3-199</infon><infon key="fpage">199</infon><infon key="issue">3</infon><infon key="journal-title">Breast Cancer Research</infon><infon key="kwd">breast cancer ductal comedo-type E-cadherin familial lobular</infon><infon key="lpage">207</infon><infon key="name_0">surname:Salahshor;given-names:Sima</infon><infon key="name_1">surname:Haixin;given-names:Lei</infon><infon key="name_2">surname:Huo;given-names:Huagang</infon><infon key="name_3">surname:Kristensen;given-names:Vessela N</infon><infon key="name_4">surname:Loman;given-names:Niklas</infon><infon key="name_5">surname:Sj&#246;berg-Margolin;given-names:Sara</infon><infon key="name_6">surname:Borg;given-names:&#197;ke</infon><infon key="name_7">surname:B&#248;rresen-Dale;given-names:Anne-Lise</infon><infon key="name_8">surname:Vorechovsky;given-names:Igor</infon><infon key="name_9">surname:Lindblom;given-names:Annika</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">3</infon><infon key="year">2001</infon><offset>0</offset><text>Low frequency of E-cadherin alterations in familial breast cancer</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>66</offset><text>The screening of 19 familial breast cancer patients, who displayed loss of heterozygosity (LOH) at the E-cadherin locus, revealed no pathogenic germline alterations. However, a somatic mutation (49-2AC) was detected in one of the tumors, which displayed ductal and lobular histology. A study also screened for mutations in other families with breast, gastric, and colon cancers to determine if this change is likely to increase the risk of</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1446</offset><text>Many people with breast cancer have E-cadherin alterations, a type of antigen that is present in high levels in breast tumours. The presence of E-cadherin alterations in breast cancer is thought to be due to the effect of E-cadherin on the immune system. It is estimated that about 2.5 million women in the UK suffer from E-cadherin alterations, which can lead to the development of cancer. It is also thought that around 1.5% of breast cancers are caused by E-cadherin alterations. The presence of E-cadherin alterations in breast tumours has been associated with an increased risk of developing breast cancer, as well as other diseases.

E-cadherin is expressed in the breast gland, and</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>1455</offset><text>Defining the topic:</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1469</offset><text>The presence of E-cadherin (CDH1) on the cell surface in most epithelial tissues is rapidly increasing evidence that this product plays a part in epitomizing epithelialic tumourigenesis. Germline mutations in E&#8211;cadraledolus have been described in families with early-onset diffuse gastric cancer and loss of function of this gene has been implicated in the pathogenesis of early stage colorectal cancer, while its expression is reduced in 50% of invasive ductal carcinoma, but genes expressed within both</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2468</offset><text>A study of a family with diffuse gastric cancer revealed the presence of an E-cadherin germline mutation that cosegregates with this disease. This missense mutation in exon 12 (Ala592Thr) was also found in the mother of the index patient, who had ductal breast cancer. To investigate whether this altered the predisposing factor to breast Cancer, we examined 1328 patients with sporadic or familial breast carcinoma and 497 control individuals.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>3141</offset><text>Materials and technique</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3163</offset><text>The screening process included the detection of 19 probands with familial breast cancer that displayed LOH at chromosome 16q, as well as 12 patients from 10 families with breast, gastric, and colorectal cancers. Additionally, nine tumours from the 19 breast Cancer cases were screened for somatic mutations, while the frequencies of the 1774GA variant (Ala592Thr) were determined in DNA extracted from 358 unconnected probrethren, 214 unrelated earlybreast cancer, BRCA1 and B</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3908</offset><text>D16S7/p79-2-23 and APRT/HUAP15 were used to identify LOH, similar to a previous study on allelic loss at 16q in familial tumours.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4073</offset><text>To screen for possible mutations in the E-cadherin gene, we used single-stranded conformation polymorphism (SSCP) and denaturing high-performance liquid chromotography (DPPLC) to screen 16 exons. The primers were similar to those described by Berx et al and Salahshor a. (manuscript submitted) but with some modifications. Only samples that displayed aberrant bands on the SSPC gel or an altered DHPLC pattern were sequenced.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>5072</offset><text>What are the results?</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5081</offset><text>In 12 patients from families with known breast, gastric or colon cancer, we found no pathogenic mutations in them and instead searched for germline alterations in 19 individuals with familial breast cancer who showed LOH at the E-cadherin locus in their tumours. We also tested nine other cases of somatic carcinoma (Fig. 2), and one case of such a change (49-2AC) in one of these cases.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5642</offset><text>A germline missense mutation in exon 12 (Ala592Thr) of E-cadherin was detected by us in a previous study of two non-BRCA1/Bastato-carrier women with familial diffuse gastric cancer. Although the penetrance was not complete, it was present in the mother's ductal breast cancer at 65 years old. In family 205 (Fig. 1b, II:2), one of the women showed the Ala592-Thr variant. Her two sisters, who had no unusually exhibited this type of breast</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7328</offset><text>The screening of all 126 BRCA1 or BRAC2 carriers from various families resulted in the discovery of the mutation in one patient with a BRAF1 germline mutation (delC2594) in family 4056. A sample from her sister was also present, and she shared the Ala592Thr variant (Fig. 1d). As both tumours were of ductal type, they were not likely to have predispose to breast cancer because neither of these had been caused by another germ line BRC1 mutation.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>8318</offset><text>The debate revolves around the topic of education.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8330</offset><text>There have been only 17 cases of E-cadherin germline mutations in diffuse gastric cancer families, while the frequency of such mutation (often fewer than 5&#8211;7 years) in breast cancer reported by other groups is relatively low. In contrast, 10 families that included breast, gastrin or colon cancer patients showed no pathogenic alteration; however, these mutation(s) were found to be less common in women with a higher percentage of germplasm than those with aninherited predisposition to breast Cancer.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9062</offset><text>Despite being found in two different groups, the frequency of Ala592Thr alteration in those groups did not align with their risk factors for breast cancer. However, other studies have suggested that germline E-cadherin mutations may have an impact on breast tumor phenotype.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10168</offset><text>In summary, the results of this study and earlier data indicate that a germline E-cadherin mutation is not primarily responsible for breast cancer, but these findings suggest that germlines and somatic mutations in this gene may impact tumour phenotypic divergence and prognosis, as well as other genetic changes or epigenetic changes.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>10754</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10767</offset><text>The presence of E-cadherin (CDH1) on the cell surface in most epithelial tissues is rapidly increasing evidence that this mammalian E&#8211;cadurh&#233;rin gene product plays a role in tumourigenesis, with loss of function having been found to cause increased proliferation and invasion of many malignant epithelium tumours, mutations in E</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12359</offset><text>Despite evidence suggesting that E-cadherin mutation may contribute to the development of hereditary gastric cancer, there is no conclusive research on whether this is true. To further investigate the possible role of E-3 cancer in breast cancer prevention, we examined all 16 exons of human epidermal medullary hormone (ECH) in 31 breast carcinoma patients (out of 10 families) who had not been diagnosed with BRCA1 or BRAF2 and had no family history. Twelve of these patients had LOH at 16q in their tumour that had either genetic</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13336</offset><text>Our study examined 1328 patients with sporadic or familial breast cancer and 497 individuals who were control subjects. In one case, we found an E-cadherin germline mutation that cosegregated with the previous study. This mutation was also present in the mother of the index patient, who had ductal breast Cancer, and also in another study where we observed a missense mutation in exon 12 (Ala592Thr) which may be linked to breast carcinoma.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>14001</offset><text>Materials and method</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>14022</offset><text>Cases</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>14028</offset><text>Cases screened for mutations in the E-cadherin gene</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14080</offset><text>Nineteen women with breast cancer who exhibited LOH at 16q were included in the present study. All of these index patients had a positive family history (more than one first- or second-degree relative with breast cancer). Ten of the 19 cases were of ductal histology, one case was both ductal and lobular, two cases were lobular only and one case was medullar. For five other cases information regarding histology was not available. Nine tumours (four ductal, two lobular, one with both ductal and lobular, and two cases with unknown histology) from these 19 patients were also tested for somatic mutations in E-cadherin.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14702</offset><text>In order to examine whether germline mutations in E-cadherin are involved in familial breast, gastric and colon cancer, 12 patients from 10 such families were also included in the present study. Six of those 12 cases had breast cancer, five had colon cancer, and one was affected with both breast and colon cancer. The histology of the breast and gastric cancers in this group was not available for study.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>15108</offset><text>Individuals genotyped for the Ala592Thr variant</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>15156</offset><text>The frequencies of Ala592Thr variant were determined in DNA extracted from blood of 358 probands with familial breast cancer, 214 unrelated early-onset breast cancer patients (age of onset &lt;41 years), 126 unrelated BRCA1 or BRCA2 carriers, and 604 unselected breast cancer patients from consecutive series. In addition 497 control patients were genotyped, who were considered to represent the general populations of Sweden and Norway. The Norwegian control individuals (a total of 244) included 177 healthy female individuals obtained through the Norwegian Population Registry as a population-based series of women aged 20-44 years from the Oslo area, and 67 healthy women (aged 55-79 years) from a mammographic screening programme from Bergen area. The Swedish control individuals (a total of 253) were healthy relatives of individuals who were counseled at the Karolinska hospital.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16040</offset><text>In the present study, 'familial breast cancer cases' are defined as patients with more than one first- or second-degree relative with breast cancer, regardless of age. All familial cases had already been tested for germline mutations in the BRCA1 and BRCA2 genes.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>16304</offset><text>Determination of loss of heterozygosity</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16344</offset><text>In the previous study of allelic loss at 16q in familial tumours the two markers D16S7/p79-2-23 and APRT/HUAP15, which map to 16q24.3, were used. Both markers are distal to E-cadherin.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>16529</offset><text>Mutation analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>16547</offset><text>Polymerase chain reaction/single-stranded conformation polymorphism</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16615</offset><text>SSCP was used to screen 16 exons of the E-cadherin gene for the presence of alterations, as described by Berx et al and Salahshor et al (manuscript submitted), but with some modification.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>16803</offset><text>Denaturing high-performance liquid chromatography</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16853</offset><text>DHPLC was carried out on automated instrumentation equipped with a DNA-separation column (Wave&#174; system; Transgenomic). PCR and Taq Gold&#8482; enzyme (Applied Biosystems Inc ABI) were used to amplify all 16 exons of E-cadherin (96&#176;C, 15 min; 94&#176;C, 30 s; 50-70&#176;C, 30 s; 72&#176;C, 45 s for 30 cycles; 72&#176;C, 2 min). The primers used were as described previously (Salahshor S, et al, manuscript submitted). Heteroduplexes and homoduplexes were formed when the PCR products were hybridized by heating to 95&#176;C (for 5 min) and cooling slowly (by 1.5&#176;C/min, 47 cycles). Five microlitres of each PCR product were then analyzed using the Wave&#174; system (Transgenomic). DNA was eluted with a mixture of bufferA (0.1 mol/l triethylamine acetate) and buffer B (0.1 mol/l triethylamine acetate, 25% acetonitrile) at a flow rate of 0.9 ml/min. The mobile-phase gradients and the temperatures for running each exon were suggested by the Wave-Maker software (Transgenomic), based on the sequence contents. The temperatures at which PCR products were analyzed are given in Table 1. The results were analyzed using HSM7000 software (Transgenomic).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>17981</offset><text>Sequencing</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>17992</offset><text>Samples with an aberrant band on the SSCP gel or an altered DHPLC pattern were sequenced by reamplifying the corresponding exon. Sequencing was performed either manually using the ThermoSequensase (Amersham Corp) kit, or with the 377 ABI automated sequencer using the Taq-Cycle sequencing BigDye Terminator kit (Applied Biosystems Inc) according to the standard conditions recommended by the manufacturer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>18398</offset><text>Restriction enzyme digestion</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>18427</offset><text>The Ala592Thr variant was detected using a specific PCR-restriction fragment length polymorphism test. In short, two pairs of primers, E-CAD12F (TGTCTGATGT-GAATGACAGC) and E-CAD12R (TGCTGTGAAGGGAGATGTAT) were used for amplification of nucleotides 1574-1884 of E-cadherin (based on GenBank accession number Z13009). The forward primer generates an in vitro mutation at nucleotide 1772 (A&#8594;G), leading to an Hha I restriction site in the PCR product. If the endogenous mutation 1774 (G&#8594;A) is present, then the Hha I restriction endonuclease site is lost. Mutated samples are distinguished from normal samples by a 20-bp longer uncleaved exon 12 fragment on agarose gels (Salahshor S, et al, manuscript submitted).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>19142</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>19150</offset><text>Screening for E-cadherin germline alterations in familial breast cancer</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19222</offset><text>The entire coding region of the E-cadherin gene was studied, including splice sites, using PCR/SSCP and sequencing in 10 families with histories of breast, gastric and colon cancer. No pathogenic germline mutation was identified in any of the individuals screened.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19487</offset><text>Negative results were also obtained by screening for germline alterations in 19 individuals with familial breast cancer who exhibited LOH at the E-cadherin locus in their tumours. We also searched for somatic alterations in nine of these 19 cases in whom tumours were available for analysis using Wave&#174; (Transgenomic), an HLPC-based nucleic acid fragment analysis system. One somatic mutation in an exon 2 splicing site (49-2A&#8594;C) was detected in the tumour that was of both ductal and lobular histology (Fig. 2). Clinical outcomes of these 19 patients were available, with 5-12 years of follow up. The two lobular breast cancer patients had both developed distant metastases, whereas distant metastases had developed in five out of 10 patients with ductal breast cancer. The patient with ductal-lobular histology and the mutation did not have distant metastasis 8 years after surgery. One previously reported common polymorphism in E-cadherin was found in exon13 at codon 692 (GCC&#8594;GCT).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>20479</offset><text>The frequency of the Ala592Tyr missense alteration</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20530</offset><text>In a previous study of one family (family 26) with familial colon and gastric cancer (Fig. 1a) (Salahshor S, et al, manuscript submitted), we identified a germline missense alteration in exon12 (Ala592Thr) of E-cadherin. This alteration cosegregated with diffuse gastric cancer and colorectal cancer in this family, although the penetrance was not complete. The alteration was present in the index patient's mother, who had ductal breast cancer of comedo type at age 65 years (Figure 1a, II:12). In order to investigate whether this alteration was associated with an increased breast cancer risk we used a specific restriction enzyme digestion/PCR test to detect the variant, in an allelic association study of familial and sporadic breast cancer patients as well as control individuals who were considered to represent the general population.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21374</offset><text>We found the mutation in two out of 358 (0.56%) non-BRCA1/BRCA2 carrier women with familial breast cancer (families 205 and 2027). In family 205 (Fig. 1b), one woman with ductal comedo-type breast cancer at age 75 years had the Ala592Thr variant. The other available case from this family (Fig. 1b, II:2) tested negative, and the histology report was not available. In family 2027 (Fig. 1c), one woman with a breast cancer of ductal comedo type at age 37 years exhibited the Ala592Thr variant, whereas her two sisters with breast cancer at ages 45 and 51 years did not. One of the sisters had lobular breast cancer, but histopathological information on the third case was not available. Because the variant did not segregate with the disease, it is not likely that this alteration predisposes to breast cancer in either of these two families.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22217</offset><text>We also screened 126 BRCA1 or BRCA2 carriers from different families, and identified the mutation in one patient with breast cancer (family 4056) with a BRCA1 germline mutation (2594delC). It was possible to obtain a sample from her sister who also carried the BRCA1 mutation, and she was found to share the Ala592Thr variant also (Fig. 1d). Both tumours were of ductal comedo type. Because both of these tumours were caused by a germline BRCA1 mutation, the E-cadherin variant was not likely to have predisposed to breast cancer.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22748</offset><text>Among the 604 sporadic breast cancer patients, five were found to carry the Ala592Thr alteration (0.83%; Table 2). One of these was of lobular type and the other four were of ductal type. One of the ductal tumours was of comedo type, but it was not known for the other three whether they were of comedo type. Four cases with Ala592Thr alteration were also found among the 497 control patients (0.80%). The alteration was not found among any of the 214 early-onset breast cancer patients.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>23236</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>23247</offset><text>E-cadherin germline mutations in familial breast cancer</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23303</offset><text>Thus far, E-cadherin germline mutations have been reported in 17 diffuse gastric cancer families. The high rate of mutations found in the Maori families probably reflects the criteria used for selection of the families. In these families at least three first-degree relatives were affected by gastric cancer, and the age of onset of at least one case was under 40 years. In other studies, a low frequency of E-cadherin germline mutations in familial gastric cancer has been reported. The frequency of E-cadherin germline mutations in breast cancer reported thus far is low. Mutations in E-cadherin reported in lobular breast cancer cases are in most cases tumour restricted, and are not germline alterations. In the 17 gastric cancer families with germline mutations, five members from three families were also affected by breast cancer. Three of these patients from three different families had both breast and gastric cancer. One patient had developed both lobular breast cancer and diffuse-type gastric cancer. In the other cases the gastric cancers were of diffuse type, and the histology of the breast tumours was unknown. In one of these families, two patients with breast cancer only were also found; these cases were early-onset breast cancer.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24555</offset><text>In the present study, we did not find any pathogenic alterations in 10 families with cases of breast, gastric or colon cancer. We conclude that, although germline E-cadherin mutations are sometimes found in familial gastric and colon cancer, they are not frequently involved in families in which breast cancer appears to segregate as a part of an inherited predisposition for gastric and colon cancer.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>24957</offset><text>Ala592Tyr alteration and breast cancer of ductal comedo type</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>25018</offset><text>The frequency of Ala592Thr alteration, which was first identified in one family with familial diffuse gastric, colon and breast cancer (Fig. 1a), was almost the same in the different groups studied here (Table 2). In familial breast cancer cases the frequency was 0.56% in non-BRCA1/BRCA2 cases, and 0.79% in BRCA1 or BRCA2 carriers. In the sporadic cases and in the control population, the frequencies were 0.83 and 0.80%, respectively. This finding does not support an effect of this alteration in predisposing to breast cancer in general. Thus, available data thus far indicate that germline E-cadherin mutations do not constitute a major risk factor for breast cancer. However, it is quite clear that somatic alterations can have an impact on the phenotype in lobular breast cancer. The fact that many breast cancer cases with the alteration (Ala592Thr) in the present study were of the ductal comedo type may indicate a genetic basis for the phenotypic divergence caused by this germline E-cadherin alteration. Although lobular breast carcinoma and ductal breast carcinoma of comedo type differ in many respects histologically, both lack formation of more differentiated mammary gland structures such as tubules. In lobular cancer, the cell characteristically grows in thin single-cell files (so-called Indian files). The comedo cancer is a poorly differentiated ductal cancer, which is rich in mitoses, often with large intraductal masses of cells with central necroses (comedons). Neither of these cancers carry a good prognosis, but individual prognosis with breast cancer is assessed mainly by grading rather than by histological type.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>26663</offset><text>Correlation between loss of heterozygosity at 16q, tumourigenesis and metastasis in breast cancer</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26761</offset><text>If E-cadherin functions as a classical tumour suppressor gene, then loss or inactivation of the remaining normal E-cadherin allele would be an important event in tumourigenesis in individuals who carry a germline mutation. In tumours with somatic E-cadherin mutations, there is often evidence of deletion of the wild-type E-cadherin allele, whereas in cases with germline mutations in the E-cadherin gene this is not usually seen. We did not find any germline mutations in the 19 familial breast cancer cases with LOH at 16q studied here, which indicates that E-cadherin does not act as a predisposing factor for breast cancer in these families. In order to examine whether somatic alterations in this gene are involved in the carcinogenesis of these tumours, we screened for somatic mutations in nine available tumours from these cases, and we found one somatic mutation in one of the lobular cancer cases. In cases with no mutation in E-cadherin, however, inactivation of this gene could have been achieved by a variety of other mechanisms. Genetic alterations in any component of the cadherin&#8211;catenin complex appear to induce loss of adhesion function. Furthermore, epigenetic changes such as promoter region hypermethylation, post-transcriptional alteration and aberrant phosphorylation of members of the cadherin-catenin complex can dysregulate E-cadherin function. It is also possible that other gene(s) located at 16q are altered, rather than E-cadherin.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>28225</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>28236</offset><text>Despite previous reports indicating that a germline mutation in E-cadherin is not primarily responsible for breast cancer, this study has also found that other genetic changes or epigenetic events may impact the metastatic behaviour of cancer cells, leading to improved phenotypic divergence and prognosis.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>28806</offset><text>Simplified expressions.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>28819</offset><text>Denaturing high-performance liquid chromatography, LOH, polymerase chain reaction, and SSCP are the terms used to describe this process.</text></passage><passage><infon key="fpage">2128</infon><infon key="lpage">2133</infon><infon key="name_0">surname:Shimoyama;given-names:Y</infon><infon key="name_1">surname:Hirohashi;given-names:S</infon><infon key="name_2">surname:Hirano;given-names:S</infon><infon key="name_3">surname:Noguchi;given-names:M</infon><infon key="name_4">surname:Shimosato;given-names:Y</infon><infon key="name_5">surname:Takeichi;given-names:M</infon><infon key="name_6">surname:Abe;given-names:O</infon><infon key="pub-id_pmid">2702654</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="year">1989</infon><offset>28991</offset><text>Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas.</text></passage><passage><infon key="fpage">237</infon><infon key="lpage">252</infon><infon key="name_0">surname:Takeichi;given-names:M</infon><infon key="pub-id_pmid">2197976</infon><infon key="section_type">REF</infon><infon key="source">Annu Rev Biochem</infon><infon key="type">ref</infon><infon key="volume">59</infon><infon key="year">1990</infon><offset>29068</offset><text>Cadherins: a molecular family important in selective cell-cell adhesion.</text></passage><passage><infon key="fpage">168</infon><infon key="lpage">176</infon><infon key="name_0">surname:Knudsen;given-names:KA</infon><infon key="name_1">surname:Frankowski;given-names:C</infon><infon key="name_2">surname:Johnson;given-names:KR</infon><infon key="name_3">surname:Wheelock;given-names:MJ</infon><infon key="pub-id_pmid">9893268</infon><infon key="section_type">REF</infon><infon key="source">J Cell Biochem Suppl</infon><infon key="type">ref</infon><infon key="volume">30-31</infon><infon key="year">1998</infon><offset>29141</offset><text>A role for cadherins in cellular signaling and differentiation.</text></passage><passage><infon key="fpage">1731</infon><infon key="lpage">1742</infon><infon key="name_0">surname:Moll;given-names:R</infon><infon key="name_1">surname:Mitze;given-names:M</infon><infon key="name_2">surname:Frixen;given-names:UH</infon><infon key="name_3">surname:Birchmeier;given-names:W</infon><infon key="pub-id_pmid">8256859</infon><infon key="section_type">REF</infon><infon key="source">Am J Pathol</infon><infon key="type">ref</infon><infon key="volume">143</infon><infon key="year">1993</infon><offset>29205</offset><text>Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.</text></passage><passage><infon key="fpage">6107</infon><infon key="lpage">6115</infon><infon key="name_0">surname:Berx;given-names:G</infon><infon key="name_1">surname:Cleton-Jansen;given-names:AM</infon><infon key="name_2">surname:Nollet;given-names:F</infon><infon key="name_3">surname:de Leeuw;given-names:WJ</infon><infon key="name_4">surname:van de Vijver;given-names:M</infon><infon key="name_5">surname:Cornelisse;given-names:C</infon><infon key="name_6">surname:van Roy;given-names:F</infon><infon key="pub-id_pmid">8557030</infon><infon key="section_type">REF</infon><infon key="source">EMBO J</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">1995</infon><offset>29302</offset><text>E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.</text></passage><passage><infon key="fpage">1054</infon><infon key="lpage">1059</infon><infon key="name_0">surname:Kashiwaba;given-names:M</infon><infon key="name_1">surname:Tamura;given-names:G</infon><infon key="name_2">surname:Suzuki;given-names:Y</infon><infon key="name_3">surname:Maesawa;given-names:C</infon><infon key="name_4">surname:Ogasawara;given-names:S</infon><infon key="name_5">surname:Sakata;given-names:K</infon><infon key="name_6">surname:Satodate;given-names:R</infon><infon key="pub-id_pmid">8567396</infon><infon key="section_type">REF</infon><infon key="source">Jpn J Cancer Res</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">1995</infon><offset>29391</offset><text>Epithelial-cadherin gene is not mutated in ductal carcinomas of the breast.</text></passage><passage><infon key="fpage">2474</infon><infon key="lpage">2477</infon><infon key="name_0">surname:Zelada-Hedman;given-names:M</infon><infon key="name_1">surname:Wasteson Arver;given-names:B</infon><infon key="name_10">surname:Borresen Dale;given-names:AL</infon><infon key="name_11">surname:Lindblom;given-names:A</infon><infon key="name_2">surname:Claro;given-names:A</infon><infon key="name_3">surname:Chen;given-names:J</infon><infon key="name_4">surname:Werelius;given-names:B</infon><infon key="name_5">surname:Kok;given-names:H</infon><infon key="name_6">surname:Sandelin;given-names:K</infon><infon key="name_7">surname:Hakansson;given-names:S</infon><infon key="name_8">surname:Andersen;given-names:TI</infon><infon key="name_9">surname:Borg;given-names:A</infon><infon key="pub-id_pmid">9192828</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">1997</infon><offset>29467</offset><text>A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.</text></passage><passage><infon key="fpage">134</infon><infon key="lpage">139</infon><infon key="name_0">surname:Chen;given-names:J</infon><infon key="name_1">surname:Hedman;given-names:MZ</infon><infon key="name_2">surname:Arver;given-names:BW</infon><infon key="name_3">surname:Sigurdsson;given-names:S</infon><infon key="name_4">surname:Eyfjord;given-names:JE</infon><infon key="name_5">surname:Lindblom;given-names:A</infon><infon key="pub-id_pmid">9781057</infon><infon key="section_type">REF</infon><infon key="source">Eur J Hum Genet</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1998</infon><offset>29571</offset><text>BRCA2 germline mutations in Swedish breast cancer families.</text></passage><passage><infon key="fpage">223</infon><infon key="lpage">226</infon><infon key="name_0">surname:Arver;given-names:B</infon><infon key="name_1">surname:Claro;given-names:A</infon><infon key="name_2">surname:Langerod;given-names:A</infon><infon key="name_3">surname:Borresen-Dale;given-names:A-L</infon><infon key="name_4">surname:Lindblom;given-names:A</infon><infon key="pub-id_pmid">10464672</infon><infon key="section_type">REF</infon><infon key="source">Genet Test</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">1999</infon><offset>29631</offset><text>BRCA1 screening in patients with a family history of breast or ovarion cancer.</text></passage><passage><infon key="fpage">4356</infon><infon key="lpage">4361</infon><infon key="name_0">surname:Lindblom;given-names:A</infon><infon key="name_1">surname:Skoog;given-names:L</infon><infon key="name_2">surname:Rotstein;given-names:S</infon><infon key="name_3">surname:Werelius;given-names:B</infon><infon key="name_4">surname:Larsson;given-names:C</infon><infon key="name_5">surname:Nordenskj&#246;ld;given-names:M</infon><infon key="pub-id_pmid">8364930</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">1993</infon><offset>29710</offset><text>Loss of heterozygosity in familial breast carcinomas.</text></passage><passage><infon key="fpage">98</infon><infon key="lpage">102</infon><infon key="name_0">surname:Risinger;given-names:JI</infon><infon key="name_1">surname:Berchuck;given-names:A</infon><infon key="name_2">surname:Kohler;given-names:MF</infon><infon key="name_3">surname:Boyd;given-names:J</infon><infon key="pub-id_pmid">8075649</infon><infon key="section_type">REF</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1994</infon><offset>29764</offset><text>Mutations of the E-cadherin gene in human gynecologic cancers.</text></passage><passage><infon key="fpage">402</infon><infon key="lpage">405</infon><infon key="name_0">surname:Guilford;given-names:P</infon><infon key="name_1">surname:Hopkins;given-names:J</infon><infon key="name_2">surname:Harraway;given-names:J</infon><infon key="name_3">surname:McLeod;given-names:M</infon><infon key="name_4">surname:McLeod;given-names:N</infon><infon key="name_5">surname:Harawira;given-names:P</infon><infon key="name_6">surname:Taite;given-names:H</infon><infon key="name_7">surname:Scoular;given-names:R</infon><infon key="name_8">surname:Miller;given-names:A</infon><infon key="name_9">surname:Reeve;given-names:AE</infon><infon key="pub-id_pmid">9537325</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">392</infon><infon key="year">1998</infon><offset>29827</offset><text>E-cadherin germline mutations in familial gastric cancer.</text></passage><passage><infon key="fpage">249</infon><infon key="lpage">255</infon><infon key="name_0">surname:Guilford;given-names:PJ</infon><infon key="name_1">surname:Hopkins;given-names:JBW</infon><infon key="name_10">surname:Toro;given-names:TT</infon><infon key="name_11">surname:Lee;given-names:D</infon><infon key="name_12">surname:Limacher;given-names:JM</infon><infon key="name_13">surname:Shaw;given-names:DW</infon><infon key="name_14">surname:Findlay;given-names:MPN</infon><infon key="name_15">surname:Reeve;given-names:AE</infon><infon key="name_2">surname:Grady;given-names:WM</infon><infon key="name_3">surname:Markowitz;given-names:SD</infon><infon key="name_4">surname:Willis;given-names:J</infon><infon key="name_5">surname:Lynch;given-names:H</infon><infon key="name_6">surname:Rajput;given-names:A</infon><infon key="name_7">surname:Wiesner;given-names:GL</infon><infon key="name_8">surname:Lindor;given-names:NM</infon><infon key="name_9">surname:Burgart;given-names:LJ</infon><infon key="pub-id_pmid">10477433</infon><infon key="section_type">REF</infon><infon key="source">Hum Mutat</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">1999</infon><offset>29885</offset><text>E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer.</text></passage><passage><infon key="fpage">4086</infon><infon key="lpage">4089</infon><infon key="name_0">surname:Gayther;given-names:SA</infon><infon key="name_1">surname:Gorringe;given-names:KL</infon><infon key="name_10">surname:MacLeod;given-names:P</infon><infon key="name_11">surname:Powell;given-names:SM</infon><infon key="name_12">surname:Jackson;given-names:CE</infon><infon key="name_13">surname:Ponder;given-names:BA</infon><infon key="name_14">surname:Caldas;given-names:C</infon><infon key="name_2">surname:Ramus;given-names:SJ</infon><infon key="name_3">surname:Huntsman;given-names:D</infon><infon key="name_4">surname:Roviello;given-names:F</infon><infon key="name_5">surname:Grehan;given-names:N</infon><infon key="name_6">surname:Machado;given-names:JC</infon><infon key="name_7">surname:Pinto;given-names:E</infon><infon key="name_8">surname:Seruca;given-names:R</infon><infon key="name_9">surname:Halling;given-names:K</infon><infon key="pub-id_pmid">9751616</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">58</infon><infon key="year">1998</infon><offset>29988</offset><text>Identification of germ-line E-cadherin mutations in gastric cancer families of European origin.</text></passage><passage><infon key="fpage">607</infon><infon key="lpage">610</infon><infon key="name_0">surname:Richards;given-names:FM</infon><infon key="name_1">surname:McKee;given-names:SA</infon><infon key="name_2">surname:Rajpar;given-names:MH</infon><infon key="name_3">surname:Cole;given-names:TR</infon><infon key="name_4">surname:Evans;given-names:DG</infon><infon key="name_5">surname:Jankowski;given-names:JA</infon><infon key="name_6">surname:McKeown;given-names:C</infon><infon key="name_7">surname:Sander;given-names:DS</infon><infon key="name_8">surname:Maher;given-names:ER</infon><infon key="pub-id_pmid">10072428</infon><infon key="section_type">REF</infon><infon key="source">Hum Mol Genet</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1999</infon><offset>30084</offset><text>Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer.</text></passage><passage><infon key="fpage">177</infon><infon key="lpage">180</infon><infon key="name_0">surname:Yoon;given-names:K-A</infon><infon key="name_1">surname:Ku;given-names:J-L</infon><infon key="name_2">surname:Yang;given-names:H-K</infon><infon key="name_3">surname:Kim;given-names:WH</infon><infon key="name_4">surname:Park;given-names:SY</infon><infon key="name_5">surname:Park;given-names:J-G</infon><infon key="pub-id_pmid">10319582</infon><infon key="section_type">REF</infon><infon key="source">J Hum Genet</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">1999</infon><offset>30187</offset><text>Germline mutations of E-Cadherin gene in Korean familial gastric cancer patients.</text></passage><passage><infon key="fpage">337</infon><infon key="lpage">342</infon><infon key="name_0">surname:Keller;given-names:G</infon><infon key="name_1">surname:Vogelsang;given-names:H</infon><infon key="name_10">surname:Hofler;given-names:H</infon><infon key="name_2">surname:Becker;given-names:I</infon><infon key="name_3">surname:Hutter;given-names:J</infon><infon key="name_4">surname:Ott;given-names:K</infon><infon key="name_5">surname:Candidus;given-names:S</infon><infon key="name_6">surname:Grundei;given-names:T</infon><infon key="name_7">surname:Becker;given-names:K</infon><infon key="name_8">surname:Mueller;given-names:J</infon><infon key="name_9">surname:Siewert;given-names:J</infon><infon key="pub-id_pmid">10433926</infon><infon key="section_type">REF</infon><infon key="source">Am J Pathol</infon><infon key="type">ref</infon><infon key="volume">155</infon><infon key="year">1999</infon><offset>30269</offset><text>Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation.</text></passage><passage><infon key="fpage">568</infon><infon key="lpage">570</infon><infon key="name_0">surname:Rahman;given-names:N</infon><infon key="name_1">surname:Stone;given-names:JG</infon><infon key="name_10">surname:A'Hern;given-names:R</infon><infon key="name_11">surname:Stratton;given-names:MR</infon><infon key="name_12">surname:Houlston;given-names:RS</infon><infon key="name_2">surname:Coleman;given-names:G</infon><infon key="name_3">surname:Gusterson;given-names:B</infon><infon key="name_4">surname:Seal;given-names:S</infon><infon key="name_5">surname:Marossy;given-names:A</infon><infon key="name_6">surname:Lakhani;given-names:SR</infon><infon key="name_7">surname:Ward;given-names:A</infon><infon key="name_8">surname:Nash;given-names:A</infon><infon key="name_9">surname:McKinna;given-names:A</infon><infon key="pub-id_pmid">10682667</infon><infon key="section_type">REF</infon><infon key="source">Br J Cancer</infon><infon key="type">ref</infon><infon key="volume">82</infon><infon key="year">2000</infon><offset>30394</offset><text>Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene.</text></passage><passage><infon key="fpage">1919</infon><infon key="lpage">1925</infon><infon key="name_0">surname:Berx;given-names:G</infon><infon key="name_1">surname:Cleton-Jansen;given-names:AM</infon><infon key="name_2">surname:Strumane;given-names:K</infon><infon key="name_3">surname:de Leeuw;given-names:WJ</infon><infon key="name_4">surname:Nollet;given-names:F</infon><infon key="name_5">surname:van Roy;given-names:F</infon><infon key="name_6">surname:Cornelisse;given-names:C</infon><infon key="pub-id_pmid">8934538</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1996</infon><offset>30500</offset><text>E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain.</text></passage><passage><infon key="fpage">403</infon><infon key="lpage">410</infon><infon key="name_0">surname:Elston;given-names:CW</infon><infon key="name_1">surname:Ellis;given-names:IO</infon><infon key="pub-id_pmid">1757079</infon><infon key="section_type">REF</infon><infon key="source">Histopathology</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">1991</infon><offset>30642</offset><text>Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.</text></passage><passage><infon key="fpage">1438</infon><infon key="lpage">1448</infon><infon key="name_0">surname:Garne;given-names:JP</infon><infon key="name_1">surname:Aspegren;given-names:K</infon><infon key="name_2">surname:Linell;given-names:F</infon><infon key="name_3">surname:Rank;given-names:F</infon><infon key="name_4">surname:Ranstam;given-names:J</infon><infon key="pub-id_pmid">8111711</infon><infon key="section_type">REF</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">73</infon><infon key="year">1994</infon><offset>30801</offset><text>Primary prognostic factors in invasive breast cancer with special reference to ductal carcinoma and histologic malignancy grade.</text></passage><passage><infon key="fpage">803</infon><infon key="lpage">804</infon><infon key="name_0">surname:Becker;given-names:KF</infon><infon key="name_1">surname:Atkinson;given-names:MJ</infon><infon key="name_2">surname:Reich;given-names:U</infon><infon key="name_3">surname:Huang;given-names:HH</infon><infon key="name_4">surname:Nekarda;given-names:H</infon><infon key="name_5">surname:Siewert;given-names:JR</infon><infon key="name_6">surname:Hofler;given-names:H</infon><infon key="pub-id_pmid">8353498</infon><infon key="section_type">REF</infon><infon key="source">Hum Mol Genet</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1993</infon><offset>30930</offset><text>Exon skipping in the E-cadherin gene transcript in metastatic human gastric carcinomas.</text></passage><passage><infon key="fpage">225</infon><infon key="lpage">233</infon><infon key="name_0">surname:Suzuki;given-names:H</infon><infon key="name_1">surname:Komiya;given-names:A</infon><infon key="name_2">surname:Emi;given-names:M</infon><infon key="name_3">surname:Kuramochi;given-names:H</infon><infon key="name_4">surname:Shiraishi;given-names:T</infon><infon key="name_5">surname:Yatani;given-names:R</infon><infon key="name_6">surname:Shimazaki;given-names:J</infon><infon key="pub-id_pmid">8946204</infon><infon key="section_type">REF</infon><infon key="source">Genes Chromosomes Cancer</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">1996</infon><offset>31018</offset><text>Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers.</text></passage><passage><infon key="fpage">1153</infon><infon key="lpage">1159</infon><infon key="name_0">surname:Tamura;given-names:G</infon><infon key="name_1">surname:Sakata;given-names:K</infon><infon key="name_2">surname:Nishizuka;given-names:S</infon><infon key="name_3">surname:Maesawa;given-names:C</infon><infon key="name_4">surname:Suzuki;given-names:Y</infon><infon key="name_5">surname:Iwaya;given-names:T</infon><infon key="name_6">surname:Terashima;given-names:M</infon><infon key="name_7">surname:Saito;given-names:K</infon><infon key="name_8">surname:Satodate;given-names:R</infon><infon key="pub-id_pmid">9045944</infon><infon key="section_type">REF</infon><infon key="source">Jpn J Cancer Res</infon><infon key="type">ref</infon><infon key="volume">87</infon><infon key="year">1996</infon><offset>31130</offset><text>Inactivation of the E-cadherin gene in primary gastric carcinomas and gastric carcinoma cell lines.</text></passage><passage><infon key="fpage">843</infon><infon key="lpage">848</infon><infon key="name_0">surname:Muta;given-names:H</infon><infon key="name_1">surname:Noguchi;given-names:M</infon><infon key="name_2">surname:Kanai;given-names:Y</infon><infon key="name_3">surname:Ochiai;given-names:A</infon><infon key="name_4">surname:Nawata;given-names:H</infon><infon key="name_5">surname:Hirohashi;given-names:S</infon><infon key="pub-id_pmid">8797891</infon><infon key="section_type">REF</infon><infon key="source">Jpn J Cancer Res</infon><infon key="type">ref</infon><infon key="volume">87</infon><infon key="year">1996</infon><offset>31230</offset><text>E-cadherin gene mutations in signet ring cell carcinoma of the stomach.</text></passage><passage><infon key="fpage">32</infon><infon key="lpage">38</infon><infon key="name_0">surname:Soares;given-names:P</infon><infon key="name_1">surname:Berx;given-names:G</infon><infon key="name_2">surname:van Roy;given-names:F</infon><infon key="name_3">surname:Sobrinho-Simoes;given-names:M</infon><infon key="pub-id_pmid">8985087</infon><infon key="section_type">REF</infon><infon key="source">Int J Cancer</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">1997</infon><offset>31302</offset><text>E-cadherin gene alterations are rare events in thyroid tumors.</text></passage><passage><infon key="fpage">1035</infon><infon key="lpage">1039</infon><infon key="name_0">surname:Kanai;given-names:Y</infon><infon key="name_1">surname:Oda;given-names:T</infon><infon key="name_2">surname:Tsuda;given-names:H</infon><infon key="name_3">surname:Ochiai;given-names:A</infon><infon key="name_4">surname:Hirohashi;given-names:S</infon><infon key="pub-id_pmid">7961105</infon><infon key="section_type">REF</infon><infon key="source">Jpn J Cancer Res</infon><infon key="type">ref</infon><infon key="volume">85</infon><infon key="year">1994</infon><offset>31365</offset><text>Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast.</text></passage><passage><infon key="fpage">171</infon><infon key="name_0">surname:Becker;given-names:KF</infon><infon key="name_1">surname:Reich;given-names:U</infon><infon key="name_2">surname:Schott;given-names:C</infon><infon key="name_3">surname:Becker;given-names:I</infon><infon key="name_4">surname:Berx;given-names:G</infon><infon key="name_5">surname:van Roy;given-names:F</infon><infon key="name_6">surname:Hofler;given-names:H</infon><infon key="pub-id_pmid">10094558</infon><infon key="section_type">REF</infon><infon key="source">Hum Mutat</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1999</infon><offset>31448</offset><text>Identification of eleven novel tumor-associated E-cadherin mutations. Mutations in brief no. 215. Online.</text></passage><passage><infon key="fpage">1858</infon><infon key="lpage">1862</infon><infon key="name_0">surname:Oda;given-names:T</infon><infon key="name_1">surname:Kanai;given-names:Y</infon><infon key="name_2">surname:Oyama;given-names:T</infon><infon key="name_3">surname:Yoshiura;given-names:K</infon><infon key="name_4">surname:Shimoyama;given-names:Y</infon><infon key="name_5">surname:Birchmeier;given-names:W</infon><infon key="name_6">surname:Sugimura;given-names:T</infon><infon key="name_7">surname:Hirohashi;given-names:S</infon><infon key="pub-id_pmid">8127895</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">1994</infon><offset>31554</offset><text>E-cadherin gene mutations in human gastric carcinoma cell lines.</text></passage><passage><infon key="fpage">3845</infon><infon key="lpage">3852</infon><infon key="name_0">surname:Becker;given-names:KF</infon><infon key="name_1">surname:Atkinson;given-names:MJ</infon><infon key="name_2">surname:Reich;given-names:U</infon><infon key="name_3">surname:Becker;given-names:I</infon><infon key="name_4">surname:Nekarda;given-names:H</infon><infon key="name_5">surname:Siewert;given-names:JR</infon><infon key="name_6">surname:Hofler;given-names:H</infon><infon key="pub-id_pmid">8033105</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">1994</infon><offset>31619</offset><text>E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.</text></passage><passage><infon key="fpage">394</infon><infon key="lpage">402</infon><infon key="name_0">surname:Siitonen;given-names:SM</infon><infon key="name_1">surname:Kononen;given-names:JT</infon><infon key="name_2">surname:Helin;given-names:HJ</infon><infon key="name_3">surname:Rantala;given-names:IS</infon><infon key="name_4">surname:Holli;given-names:KA</infon><infon key="name_5">surname:Isola;given-names:JJ</infon><infon key="pub-id_pmid">8604681</infon><infon key="section_type">REF</infon><infon key="source">Am J Clin Pathol</infon><infon key="type">ref</infon><infon key="volume">105</infon><infon key="year">1996</infon><offset>31695</offset><text>Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer.</text></passage><passage><infon key="fpage">1237</infon><infon key="lpage">1241</infon><infon key="name_0">surname:Jones;given-names:JL</infon><infon key="name_1">surname:Royall;given-names:JE</infon><infon key="name_2">surname:Walker;given-names:RA</infon><infon key="pub-id_pmid">8883410</infon><infon key="section_type">REF</infon><infon key="source">Br J Cancer</infon><infon key="type">ref</infon><infon key="volume">74</infon><infon key="year">1996</infon><offset>31801</offset><text>E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma.</text></passage><passage><infon key="fpage">262</infon><infon key="lpage">266</infon><infon key="name_0">surname:Bukholm;given-names:IK</infon><infon key="name_1">surname:Nesland;given-names:JM</infon><infon key="name_2">surname:Karesen;given-names:R</infon><infon key="name_3">surname:Jacobsen;given-names:U</infon><infon key="name_4">surname:Borresen-Dale;given-names:AL</infon><infon key="pub-id_pmid">9771479</infon><infon key="section_type">REF</infon><infon key="source">J Pathol</infon><infon key="type">ref</infon><infon key="volume">185</infon><infon key="year">1998</infon><offset>31894</offset><text>E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma.</text></passage><passage><infon key="fpage">3707</infon><infon key="lpage">3711</infon><infon key="name_0">surname:Lindblom;given-names:A</infon><infon key="name_1">surname:Rotstein;given-names:S</infon><infon key="name_2">surname:Skoog;given-names:L</infon><infon key="name_3">surname:Nordenskj&#246;ld;given-names:M</infon><infon key="name_4">surname:Larsson;given-names:C</infon><infon key="pub-id_pmid">8339280</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">1993</infon><offset>32014</offset><text>Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases.</text></passage><passage><infon key="fpage">101</infon><infon key="lpage">107</infon><infon key="name_0">surname:Cleton-Jansen;given-names:AM</infon><infon key="name_1">surname:Moerland;given-names:EW</infon><infon key="name_2">surname:Kuipers-Dijkshoorn;given-names:NJ</infon><infon key="name_3">surname:Callen;given-names:DF</infon><infon key="name_4">surname:Sutherland;given-names:GR</infon><infon key="name_5">surname:Hansen;given-names:B</infon><infon key="name_6">surname:Devilee;given-names:P</infon><infon key="name_7">surname:Cornelisse;given-names:CJ</infon><infon key="pub-id_pmid">7513539</infon><infon key="section_type">REF</infon><infon key="source">Genes Chromosomes Cancer</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1994</infon><offset>32134</offset><text>At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer.</text></passage><passage><infon key="fpage">177</infon><infon key="lpage">182</infon><infon key="name_0">surname:Caligo;given-names:MA</infon><infon key="name_1">surname:Polidoro;given-names:L</infon><infon key="name_2">surname:Ghimenti;given-names:C</infon><infon key="name_3">surname:Campani;given-names:D</infon><infon key="name_4">surname:Cecchetti;given-names:D</infon><infon key="name_5">surname:Bevilacqua;given-names:G</infon><infon key="pub-id_pmid">9625819</infon><infon key="section_type">REF</infon><infon key="source">Int J Oncol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1998</infon><offset>32239</offset><text>A region on the long arm of chromosome 16 is frequently deleted in metastatic node-negative breast cancer.</text></passage><passage><infon key="fpage">1935</infon><infon key="lpage">1937</infon><infon key="name_0">surname:Stone;given-names:J</infon><infon key="name_1">surname:Bevan;given-names:S</infon><infon key="name_2">surname:Cunningham;given-names:D</infon><infon key="name_3">surname:Hill;given-names:A</infon><infon key="name_4">surname:Rahman;given-names:N</infon><infon key="name_5">surname:Peto;given-names:J</infon><infon key="name_6">surname:Marossy;given-names:A</infon><infon key="name_7">surname:Houlston;given-names:R</infon><infon key="pub-id_pmid">10206317</infon><infon key="section_type">REF</infon><infon key="source">Br J Cancer</infon><infon key="type">ref</infon><infon key="volume">79</infon><infon key="year">1999</infon><offset>32346</offset><text>Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer.</text></passage><passage><infon key="fpage">1445</infon><infon key="lpage">1447</infon><infon key="name_0">surname:Iida;given-names:S</infon><infon key="name_1">surname:Akiyama;given-names:Y</infon><infon key="name_2">surname:Ichikawa;given-names:W</infon><infon key="name_3">surname:Yamashita;given-names:T</infon><infon key="name_4">surname:Nomizu;given-names:T</infon><infon key="name_5">surname:Nihei;given-names:Z</infon><infon key="name_6">surname:Sugihara;given-names:K</infon><infon key="name_7">surname:Yuasa;given-names:Y</infon><infon key="pub-id_pmid">10389930</infon><infon key="section_type">REF</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1999</infon><offset>32437</offset><text>Infrequent germ-line mutation of the E-cadherin gene in Japanese familial gastric cancer kindreds.</text></passage><passage><infon key="fpage">3585</infon><infon key="lpage">3590</infon><infon key="name_0">surname:Morton;given-names:RA</infon><infon key="name_1">surname:Ewing;given-names:CM</infon><infon key="name_2">surname:Nagafuchi;given-names:A</infon><infon key="name_3">surname:Tsukita;given-names:S</infon><infon key="name_4">surname:Isaacs;given-names:WB</infon><infon key="pub-id_pmid">8339265</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">1993</infon><offset>32536</offset><text>Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.</text></passage><passage><infon key="fpage">6282</infon><infon key="lpage">6287</infon><infon key="name_0">surname:Oyama;given-names:T</infon><infon key="name_1">surname:Kanai;given-names:Y</infon><infon key="name_2">surname:Ochiai;given-names:A</infon><infon key="name_3">surname:Akimoto;given-names:S</infon><infon key="name_4">surname:Oda;given-names:T</infon><infon key="name_5">surname:Yanagihara;given-names:K</infon><infon key="name_6">surname:Nagafuchi;given-names:A</infon><infon key="name_7">surname:Tsukita;given-names:S</infon><infon key="name_8">surname:Shibamoto;given-names:S</infon><infon key="name_9">surname:Ito;given-names:F</infon><infon key="pub-id_pmid">7954478</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">1994</infon><offset>32638</offset><text>A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines.</text></passage><passage><infon key="fpage">1972</infon><infon key="lpage">1977</infon><infon key="name_0">surname:Hiraguri;given-names:S</infon><infon key="name_1">surname:Godfrey;given-names:T</infon><infon key="name_10">surname:Baylin;given-names:S</infon><infon key="name_11">surname:Pinkel;given-names:D</infon><infon key="name_12">surname:Gray;given-names:J</infon><infon key="name_2">surname:Nakamura;given-names:H</infon><infon key="name_3">surname:Graff;given-names:J</infon><infon key="name_4">surname:Collins;given-names:C</infon><infon key="name_5">surname:Shayesteh;given-names:L</infon><infon key="name_6">surname:Doggett;given-names:N</infon><infon key="name_7">surname:Johnson;given-names:K</infon><infon key="name_8">surname:Wheelock;given-names:M</infon><infon key="name_9">surname:Herman;given-names:J</infon><infon key="pub-id_pmid">9581841</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">58</infon><infon key="year">1998</infon><offset>32800</offset><text>Mechanisms of inactivation of E-cadherin in breast cancer cell lines.</text></passage><passage><infon key="fpage">5195</infon><infon key="lpage">5199</infon><infon key="name_0">surname:Graff;given-names:JR</infon><infon key="name_1">surname:Herman;given-names:JG</infon><infon key="name_2">surname:Lapidus;given-names:RG</infon><infon key="name_3">surname:Chopra;given-names:H</infon><infon key="name_4">surname:Xu;given-names:R</infon><infon key="name_5">surname:Jarrard;given-names:DF</infon><infon key="name_6">surname:Isaacs;given-names:WB</infon><infon key="name_7">surname:Pitha;given-names:PM</infon><infon key="name_8">surname:Davidson;given-names:NE</infon><infon key="name_9">surname:Baylin;given-names:SB</infon><infon key="pub-id_pmid">7585573</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">55</infon><infon key="year">1995</infon><offset>32870</offset><text>E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.</text></passage><passage><infon key="fpage">7416</infon><infon key="lpage">7419</infon><infon key="name_0">surname:Yoshiura;given-names:K</infon><infon key="name_1">surname:Kanai;given-names:Y</infon><infon key="name_2">surname:Ochiai;given-names:A</infon><infon key="name_3">surname:Shimoyama;given-names:Y</infon><infon key="name_4">surname:Sugimura;given-names:T</infon><infon key="name_5">surname:Hirohashi;given-names:S</infon><infon key="pub-id_pmid">7543680</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">92</infon><infon key="year">1995</infon><offset>32969</offset><text>Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.</text></passage><passage><infon key="fpage">519</infon><infon key="lpage">522</infon><infon key="name_0">surname:Shibata;given-names:T</infon><infon key="name_1">surname:Gotoh;given-names:M</infon><infon key="name_2">surname:Ochiai;given-names:A</infon><infon key="name_3">surname:Hirohashi;given-names:S</infon><infon key="pub-id_pmid">8074697</infon><infon key="section_type">REF</infon><infon key="source">Biochem Biophys Res Commun</infon><infon key="type">ref</infon><infon key="volume">203</infon><infon key="year">1994</infon><offset>33062</offset><text>Association of plakoglobin with APC, a tumor suppressor gene product, and its regulation by tyrosine phosphorylation.</text></passage><passage><infon key="section_type">FIG</infon><infon key="type">title_1</infon><offset>33180</offset><text>Figures and Tables</text></passage><passage><infon key="file">BCR-3-3-199-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>33199</offset><text>Pedigrees of the four families with Ala592Thr missense alteration. BR, breast cancer; GA, gastric cancer; OV, ovarian cancer; GI, gastrointestinal cancer; AD, colonic adenomas; Endo, endometrial cancer; M, positive for the Ala592Thr variant; N, wild-type E-cadherin.</text></passage><passage><infon key="file">BCR-3-3-199-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>33466</offset><text>The 3' splice site alteration in the E-cadherin gene (49-2A&#8594;C) in tumor M279.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>33546</offset><text>PCR and DHPLC conditions for the mutational analysis of E-cadherin</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center"&gt;Annealing&lt;/td&gt;&lt;td align="center"&gt;Amplicon&lt;/td&gt;&lt;td align="center"&gt;DHPLC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center"&gt;temperature&lt;/td&gt;&lt;td align="center"&gt;length&lt;/td&gt;&lt;td align="center"&gt;temperature&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Exon no&lt;/td&gt;&lt;td align="center"&gt;(&#176;C)&lt;/td&gt;&lt;td align="center"&gt;(bp)&lt;/td&gt;&lt;td align="center"&gt;(&#176;C)&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;1&lt;/td&gt;&lt;td align="center"&gt;70&lt;/td&gt;&lt;td align="center"&gt;285&lt;/td&gt;&lt;td align="center"&gt;66&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;2&lt;/td&gt;&lt;td align="center"&gt;55&lt;/td&gt;&lt;td align="center"&gt;377&lt;/td&gt;&lt;td align="center"&gt;62&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;3&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;352&lt;/td&gt;&lt;td align="center"&gt;58, 61&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;4&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;351&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;5&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;398&lt;/td&gt;&lt;td align="center"&gt;58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;6&lt;/td&gt;&lt;td align="center"&gt;58&lt;/td&gt;&lt;td align="center"&gt;246&lt;/td&gt;&lt;td align="center"&gt;59&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;7&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;329&lt;/td&gt;&lt;td align="center"&gt;60, 62, 64&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;8&lt;/td&gt;&lt;td align="center"&gt;58&lt;/td&gt;&lt;td align="center"&gt;225&lt;/td&gt;&lt;td align="center"&gt;59, 62&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;9&lt;/td&gt;&lt;td align="center"&gt;55&lt;/td&gt;&lt;td align="center"&gt;252&lt;/td&gt;&lt;td align="center"&gt;59&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;10&lt;/td&gt;&lt;td align="center"&gt;55&lt;/td&gt;&lt;td align="center"&gt;309&lt;/td&gt;&lt;td align="center"&gt;58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;11&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;243&lt;/td&gt;&lt;td align="center"&gt;61&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;12&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;326&lt;/td&gt;&lt;td align="center"&gt;59, 61&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;13&lt;/td&gt;&lt;td align="center"&gt;58&lt;/td&gt;&lt;td align="center"&gt;297&lt;/td&gt;&lt;td align="center"&gt;58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;14&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;206&lt;/td&gt;&lt;td align="center"&gt;61&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;15&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;244&lt;/td&gt;&lt;td align="center"&gt;58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;16&lt;/td&gt;&lt;td align="center"&gt;60&lt;/td&gt;&lt;td align="center"&gt;318&lt;/td&gt;&lt;td align="center"&gt;59&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>33613</offset><text>	Annealing	Amplicon	DHPLC	 		temperature	length	temperature	 	Exon no	(&#176;C)	(bp)	(&#176;C)	 	1	70	285	66	 	2	55	377	62	 	3	60	352	58, 61	 	4	60	351	60	 	5	60	398	58	 	6	58	246	59	 	7	60	329	60, 62, 64	 	8	58	225	59, 62	 	9	55	252	59	 	10	55	309	58	 	11	60	243	61	 	12	60	326	59, 61	 	13	58	297	58	 	14	60	206	61	 	15	60	244	58	 	16	60	318	59	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>33954</offset><text>Frequency of Ala592Thr variant in various populations of breast cancer patients and control population</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center"&gt;No of families/&lt;/td&gt;&lt;td align="center"&gt;Frequency of&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Screened population&lt;/td&gt;&lt;td align="center"&gt;no of cases&lt;/td&gt;&lt;td align="center"&gt;Ala592Thr variant&lt;/td&gt;&lt;td align="center"&gt;Case id&lt;/td&gt;&lt;td align="left"&gt;Histopathology&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;Familial breast cancer&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;Non-&lt;italic&gt;BRCA1&lt;/italic&gt;/&lt;italic&gt;BRCA2&lt;/italic&gt; mutation carrier&lt;/td&gt;&lt;td align="center"&gt;358&lt;/td&gt;&lt;td align="center"&gt;0.56%&lt;/td&gt;&lt;td align="center"&gt;311-89D&lt;/td&gt;&lt;td align="left"&gt;Ductal comedo&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;AL-155&lt;/td&gt;&lt;td align="left"&gt;Ductal comedo&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&lt;italic&gt;BRCA1&lt;/italic&gt;/&lt;italic&gt;BRCA2&lt;/italic&gt; carrier&lt;/td&gt;&lt;td align="center"&gt;126&lt;/td&gt;&lt;td align="center"&gt;0.79%&lt;/td&gt;&lt;td align="center"&gt;BR-115&lt;/td&gt;&lt;td align="left"&gt;Ductal comedo&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;BR-119&lt;/td&gt;&lt;td align="left"&gt;Ductal comedo&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Sporadic breast cancer&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;Early-onset breast cancer&lt;/td&gt;&lt;td align="center"&gt;214&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;Unselected breast cancer&lt;/td&gt;&lt;td align="center"&gt;604&lt;/td&gt;&lt;td align="center"&gt;0.83%&lt;/td&gt;&lt;td align="center"&gt;17-S&lt;/td&gt;&lt;td align="left"&gt;Lobular&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;MB-181&lt;/td&gt;&lt;td align="left"&gt;Ductal comedo&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;MB-483&lt;/td&gt;&lt;td align="left"&gt;Ductal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;ULL-17&lt;/td&gt;&lt;td align="left"&gt;Ductal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="center"&gt;ULL-284&lt;/td&gt;&lt;td align="left"&gt;Ductal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Control population&lt;/td&gt;&lt;td align="center"&gt;495&lt;/td&gt;&lt;td align="center"&gt;0.80%&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>34057</offset><text>	No of families/	Frequency of			 	Screened population	no of cases	Ala592Thr variant	Case id	Histopathology	 	Familial breast cancer					 	&#8195;Non-BRCA1/BRCA2 mutation carrier	358	0.56%	311-89D	Ductal comedo	 				AL-155	Ductal comedo	 	&#8195;BRCA1/BRCA2 carrier	126	0.79%	BR-115	Ductal comedo	 				BR-119	Ductal comedo	 	Sporadic breast cancer					 	&#8195;Early-onset breast cancer	214	-			 	&#8195;Unselected breast cancer	604	0.83%	17-S	Lobular	 				MB-181	Ductal comedo	 				MB-483	Ductal	 				ULL-17	Ductal	 				ULL-284	Ductal	 	Control population	495	0.80%			 	</text></passage></document></collection>